Pascal Biosciences (PAS) Hits New 12-Month Low at $0.20

Shares of Pascal Biosciences Inc (CVE:PAS) hit a new 52-week low on Monday . The company traded as low as C$0.20 and last traded at C$0.21, with a volume of 40000 shares traded. The stock had previously closed at C$0.22.

The company has a market capitalization of $11.32 million and a price-to-earnings ratio of -2.87.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at

Pascal Biosciences Company Profile (CVE:PAS)

Pascal Biosciences Inc, a drug discovery and development company, researches and develops biotechnology products for the treatment of cancer and for the enhancement of immune system in Canada. Its research programs include the development of Anti-VpreB, a therapeutic monoclonal antibody for treatment of B-cell precursor acute lymphoblastic leukemia in collaboration with the University of New Mexico; optimization of novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases.

Featured Story: What are gap-up stocks?

Receive News & Ratings for Pascal Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pascal Biosciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit